These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Monoclonal antibodies MA54 and MA61 as potential reagents in the prognosis of patients with ovarian cancer.
    Author: Kobayashi H, Ohi H, Sugimura M, Shinohara H, Terao T.
    Journal: Gynecol Oncol; 1993 Apr; 49(1):80-5. PubMed ID: 8482565.
    Abstract:
    Monoclonal antibodies (moABs) MA54 and MA61 directed to the O-linked NeuAc alpha 2-6GalNAc epitope were generated by immunization with culture supernatants of lung adenocarcinoma cells. We have examined the correlation between the prognosis of patients (overall survival and progression-free survival) and circulating serum levels of CA54/61 antigen by comparison with CA125 in patients with epithelial ovarian cancer. Circulating serum CA54/61 antigen levels were determined by sandwich enzyme immunoassay kits. Serum antigen levels were elevated in 44.4% of the patients. Survival at 3 years for ovarian cancer patients with CA54/61-negative (serum CA54/61 levels < 15.2 U/ml) versus CA54/61-positive (CA54/61 > or = 15.2 U/ml) tumors was 64% versus 25% (P < 0.05). In contrast, there is no significant difference in the prognosis of patients based upon positive or negative CA125 antigen values (51% vs 67%). The overall survival rate was worse in patients with CA54/61-positive sera, indicating that positive CA54/61 levels in serum is an independent predictor of poor prognosis in ovarian cancer. In addition, CA54/61 status has been shown to be associated with early relapse of this malignancy.
    [Abstract] [Full Text] [Related] [New Search]